FOXO4-DRI

Background

FOXO4‑DRI (forkhead box O transcription factor 4–D‑retro‑inverso peptide) is a synthetic senolytic peptide designed to selectively induce apoptosis in senescent cells by disrupting the interaction between FOXO4 and p53.[13][15] It is often referred to simply as FOXO4‑DRI peptide, FOXO4‑DRI senolytic, or a FOXO4–p53 interfering peptide.[13][14][15]

The peptide was first described by Baar et al. as a rationally designed D‑retro‑inverso (DRI) sequence derived from the FOXO4 forkhead domain, conjugated to a cell‑penetrating region to enhance intracellular delivery and proteolytic stability.[13] D‑retro‑inverso peptides reverse the amino acid sequence and substitute L‑ with D‑amino acids to preserve side‑chain topology while increasing resistance to degradation.

FOXO4‑DRI emerged from work showing that senescent cells maintain viability by engaging senescence‑cell anti‑apoptotic pathways (SCAPs), among which the FOXO4–p53 complex is critical for retaining p53 in the nucleus and preventing apoptosis.[13] By targeting this axis, FOXO4‑DRI represented one of the first peptide‑based senolytics, complementing small‑molecule senolytics such as dasatinib, quercetin, fisetin, and navitoclax.[13]

To date, the development of FOXO4‑DRI has remained preclinical, with no registered human clinical trials or regulatory approvals in the United States or European Union.

Mechanism of action

Molecular target and binding

Senescent cells show increased levels of FOXO4, which binds the p53 transactivation domain and anchors p53 in the nucleus, thereby contributing to a pro‑survival, senescent state.[13][15] FOXO4‑DRI is designed to compete with endogenous FOXO4 for binding to p53, thereby disrupting the FOXO4–p53 complex.[13][15]

NMR and biophysical studies have refined the structural understanding of this interaction. The p53 transactivation domain 2 (p53 TAD2) is intrinsically disordered; FOXO4‑DRI, also disordered, binds to p53 TAD2 to form a transiently folded complex in which both the FOXO4‑derived segment and the polycationic cell‑permeable motif contribute to affinity and specificity.[4] Phosphorylation of p53, particularly within TAD, increases affinity for both FOXO4 and FOXO4‑DRI, providing a mechanistic basis for preferential targeting of stress‑ or senescence‑associated p53.[4]

Downstream effects in senescent cells

By displacing FOXO4 from p53, FOXO4‑DRI promotes nuclear exclusion of p53, leading to mitochondrial localization and activation of p53‑dependent apoptotic pathways.[13][15] In senescent Leydig cells and keloid fibroblasts, FOXO4‑DRI treatment induces p53 nuclear export, decreases p21 expression, and activates caspase‑dependent apoptosis.[5][15]

In endothelial cells, FOXO4‑DRI has been shown to modulate the p53/BCL‑2/caspase‑3 signaling pathway, decreasing anti‑apoptotic BCL‑2, increasing cleaved caspase‑3, and selectively inducing apoptosis in senescent, but not non‑senescent, endothelial cells.[6]

Collectively, these data support the classification of FOXO4‑DRI as a targeted senolytic that:

• Recognizes senescent cells indirectly through their elevated FOXO4–p53 signaling.
• Disrupts FOXO4–p53 binding at the p53 TAD2 interface.[4][13]
• Triggers p53 relocalization and intrinsic apoptosis preferentially in senescent cells.[5][6][15]

Evidence summary

Foundational FOXO4‑DRI studies (Baar et al.)

The original FOXO4‑DRI work by Baar et al. is widely cited but the full article is not open‑access in the provided results; it is summarized in later reviews and commentaries.[13][15] In that work, FOXO4‑DRI:

• Selectively induced apoptosis in various senescent fibroblast models while sparing proliferating cells.[13]
• Improved healthspan measures in progeroid and naturally aged mice, including kidney function and physical performance, after systemic administration.[13]

Specific sample sizes and dosing regimens are incompletely detailed in secondary sources; the primary paper used repeated intraperitoneal injections in progeroid and aged mice and reported reductions in p16Ink4a+ cells and improved organ function.[13]

Leydig cell aging and testosterone insufficiency

In a study on male late‑onset hypogonadism, FOXO4‑DRI was evaluated in naturally aged mice (commonly 18–24 months) to target senescent Leydig cells.[15] Key findings:

• FOXO4 and FOXO4–p53 interactions were increased in senescent Leydig cells, with nuclear p53 retention.[15]
• FOXO4‑DRI disrupted FOXO4–p53 binding, induced p53 nuclear exclusion, and triggered apoptosis selectively in senescent Leydig cells.[15]
• Treatment increased serum testosterone levels and improved Leydig cell function without overt histological toxicity in major organs.[15]

Exact group sizes and full quantitative outcomes require consultation of the original article; the accessible report describes significant functional rescue but remains limited to mouse models.[15]

Chondrocyte senescence and cartilage engineering

In a human ex vivo/in vitro study, FOXO4‑DRI was applied to in vitro–expanded human articular chondrocytes at different population doubling levels (PDLs).[11][12]

• Donor chondrocytes (from healthy human cartilage) were expanded to PDL3 and PDL9; PDL9 cells are more senescent and resemble clinically expanded cells for autologous chondrocyte implantation.[11][12]
• FOXO4‑DRI treatment removed >50% of PDL9 cells while having minimal effect on PDL3 cell numbers, indicating selective senolytic activity.[11][12]
• Senescence markers (SA‑β‑gal positivity, p16 expression, SASP‑related transcripts) were significantly reduced in treated PDL9 cultures.[11][12]
• In pellet culture, cartilage engineered from FOXO4‑DRI–pretreated PDL9 cells showed decreased senescence markers in neo‑tissue, but no clear enhancement of chondrogenic capacity compared with untreated PDL9 controls.[11][12]

This work supports senolytic efficacy in human cells ex vivo but does not provide in vivo or clinical data.

Cancer‑associated fibroblasts and radiotherapy

A preclinical study investigated targeting senescence‑like cancer‑associated fibroblasts (CAFs) in non‑small cell lung cancer (NSCLC) using FOXO4‑DRI.[14]

• Radiation‑induced senescence‑like CAFs promoted NSCLC cell proliferation and radioresistance via JAK/STAT signaling.[14]
• FOXO4‑DRI selectively induced apoptosis in these senescence‑like CAFs in vitro, reducing their pro‑tumorigenic influence.[14]
• In mouse models of NSCLC with radiotherapy, FOXO4‑DRI treatment enhanced radiosensitivity and reduced radiation‑induced pulmonary fibrosis.[14]

Sample sizes were typical of preclinical oncology (multiple mice per group); the study demonstrated mechanistic efficacy but remained preclinical.

Keloid disease

A single‑cell and organoid‑based study evaluated FOXO4‑DRI in keloid senescent fibroblasts.[5]

• Keloid tissue showed increased senescent fibroblast populations, elevated p16, and higher p53‑Ser15 phosphorylation.[5]
• FOXO4‑DRI treatment in keloid organ cultures and fibroblast models increased apoptosis, decreased G0/G1 cell fraction, and induced p53‑Ser15 nuclear exclusion.[5]
• The authors concluded that FOXO4‑DRI has potential to target the senescent microenvironment implicated in keloid growth and recurrence.[5]

These data remain preclinical and ex vivo; no human trial has tested FOXO4‑DRI in keloid patients.

Vascular aging and endothelial senescence

Recent work investigated FOXO4‑DRI in senescent endothelial cells and aged or progeroid mouse aortas.[6]

• In naturally aged and progeroid mice, systemic FOXO4‑DRI injections reduced senescence markers (p16, SA‑β‑gal) in aortic endothelium and improved measures of vascular function, such as endothelium‑dependent vasodilation.[6]
• In vitro, FOXO4‑DRI selectively induced apoptosis in senescent endothelial cells (induced by oxygen‑glucose deprivation) via the p53/BCL‑2/caspase‑3 pathway, with limited effects on non‑senescent controls.[6]

Again, these findings are limited to animal and cell models.

Other preclinical reports

• In a doxorubicin‑induced senescence model in mice, combined adriblastin (doxorubicin analogue) and FOXO4‑DRI showed moderate protection of liver morphology, with reduced leukocyte and fatty infiltration, and sex‑specific differences in response.[1]
• Bioinformatics and molecular modeling work has used FOXO4‑DRI as a prototype senolytic to analyze FOXO4–p53 interactions and to design next‑generation peptides (e.g., ES2) with enhanced potency.[9][10][13]

No completed human clinical trials of FOXO4‑DRI are indexed in ClinicalTrials.gov or major regulatory databases.

Clinical and research uses

Established/preclinical indications

To date, FOXO4‑DRI use is confined to preclinical research as a tool compound to:

• Eliminate senescent fibroblasts and improve organ function in aging models.[13][14][15]
• Target senescent chondrocytes in cartilage tissue engineering.[11][12]
• Modulate senescent Leydig cells in age‑related hypogonadism models.[15]
• Remove senescent endothelial cells in vascular aging studies.[6]
• Target senescence‑like CAFs to enhance radiotherapy and limit fibrosis in NSCLC models.[14]
• Explore senescence biology in keloid fibroblasts and scar pathology.[5]

Off‑label or investigational human use

There are no peer‑reviewed reports of controlled human administration of FOXO4‑DRI for therapeutic purposes. Any use outside experimental animal or ex vivo human tissue studies would be considered speculative and unsupported by clinical evidence.

FOXO4‑DRI should therefore be regarded as an experimental research peptide, not a clinically validated drug.

Dosing context

Published dosing information derives only from animal studies and in vitro experiments, and cannot be directly translated to humans.

• In multiple mouse studies (progeroid/aged mice, Leydig cell aging, vascular aging, NSCLC models), FOXO4‑DRI was administered via repeated intraperitoneal or intravenous injections at doses in the low mg/kg range, typically several times per week over weeks.[13][15][6][14] Precise regimens vary by study and model, and are not standardized.
• In chondrocyte and fibroblast cultures, FOXO4‑DRI is applied at micromolar concentrations for 24–72 hours to achieve selective senolysis.[11][12][5]

These regimens are experimental, optimized for preclinical endpoints (cell clearance, functional rescue) and not established for safety or efficacy in humans. No dosing guidelines, maximum tolerated doses, or pharmacokinetic data in humans have been published.

Safety profile

Preclinical toxicity observations

Across mouse and cell studies, FOXO4‑DRI has generally shown selective toxicity toward senescent cells with relative sparing of non‑senescent counterparts.[11][12][13][15] However, systematic toxicology is limited.

• In aged and progeroid mice treated systemically, FOXO4‑DRI reduced senescent cell burden and improved organ function without obvious histological damage in major organs reported in summary articles.[13]
• In Leydig cell studies, FOXO4‑DRI improved testosterone levels without apparent adverse morphological changes in testes or other tissues under the reported conditions.[15]
• In a liver morphology study combining adriblastin and FOXO4‑DRI, microscopic assessment suggested a moderate protective effect on hepatocytes with decreased leukocyte and fatty infiltration, though sex‑dependent differences were noted.[1]
• In vascular aging models, repeated FOXO4‑DRI dosing improved endothelial function and reduced senescence markers with no major organ toxicity reported in the article.[6]

In vitro, high concentrations can induce apoptosis in target senescent cells and potentially affect non‑senescent cells at sufficiently elevated doses or prolonged exposure, but the therapeutic window is not quantitatively defined.[11][12][5]

Unknowns and potential risks

Important safety domains remain insufficiently characterized:

• Immunogenicity: As a synthetic D‑retro‑inverso peptide with a cell‑penetrating motif, the potential for immune responses in humans is unknown.
• Off‑target effects: p53 is a central tumor suppressor; chronic perturbation of p53 localization or signaling in non‑senescent cells could theoretically affect oncogenic risk or tissue homeostasis, but long‑term data are lacking.
• Reproductive and developmental toxicity: Not systematically studied; Leydig cell targeting suggests potential reproductive endocrine effects.[15]
• Drug–drug interactions: No data are available.

Given these gaps, FOXO4‑DRI cannot be considered safety‑characterized for human use.

Contraindications (theoretical)

No formal contraindications are defined because the agent has not entered clinical development. Based on mechanism and preclinical data, theoretical areas of concern include:

• Conditions where p53 function is critical (e.g., active malignancy with ongoing DNA damage responses) where extensive manipulation of p53 localization might be undesirable.
• States of impaired tissue repair where senescent cells contribute to wound sealing; excessive senolysis could impair healing.

These remain speculative and require formal evaluation.

Regulatory status

As of the latest available literature:

• FOXO4‑DRI is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any indication.
• No active or completed registered human clinical trials of FOXO4‑DRI were identified in ClinicalTrials.gov or related registries in the referenced publications.[11][12][13][14][15]
• Current use is restricted to laboratory and animal research, generally under institutional animal care and biosafety oversight.

FOXO4‑DRI is therefore best categorized as a preclinical senolytic research tool, with promising mechanistic and functional data in animal and ex vivo human models, but no established clinical role or regulatory recognition in the US or EU.